CD19 and non-Hodgkin lymphoma: This is reflected by the regulatory approval of three CD19-directed CAR T cell products to date for the treatment of several non-Hodgkin lymphomas and pediatric/young adult B-acute lymphoblastic leukemia (B-ALL).